Definium Therapeutics (DFTX) Income from Continuing Operations (2019 - 2026)
Definium Therapeutics (DFTX) reported Income from Continuing Operations of 56963000.0 for Q1 2026, down 87.82% year-over-year from 467796876.25 in Q1 2025, and down 25.54% on a QoQ basis from 45373000.0 in Q4 2025.
Definium Therapeutics (DFTX) has 8 years of Income from Continuing Operations data on file, last reported at 56963000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 87.82% year-over-year to 56963000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 187484000.0 (down 80.3% YoY) and the FY2025 annual result came in at 160849000.0, down 69.96% from the prior year.
- Income from Continuing Operations slipped to 56963000.0 in Q1 2026 per DFTX's latest filing, from 45373000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 56860000.0 in Q4 2022 and bottomed at 56963000.0 in Q1 2026.
- The 5-year median for Income from Continuing Operations is 21808000.0 (2024), against an average of 23333941.18.
- The widest annual swing landed in 2022, when Income from Continuing Operations surged 104.95%; it then plunged 137.83% in 2023.
- Tracing DFTX's Income from Continuing Operations over 5 years: stood at 56860000.0 in 2022, then tumbled by 137.83% to 21510000.0 in 2023, then plunged by 38.72% to 29839000.0 in 2024, then sank by 52.06% to 45373000.0 in 2025, then decreased by 25.54% to 56963000.0 in 2026.
- Per Business Quant, the three latest DFTX Income from Continuing Operations figures stand at 56963000.0 (Q1 2026), 45373000.0 (Q4 2025), and 44681000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Definium Therapeutics | 2.42 Bn | 2.06 Bn | - | -56.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -56.96 Mn |
| Dec 31, 2025 | -45.37 Mn |
| Sep 30, 2025 | -44.68 Mn |
| Jun 30, 2025 | -40.47 Mn |
| Mar 31, 2025 | -30.33 Mn |
| Dec 31, 2024 | -29.84 Mn |
| Sep 30, 2024 | -22.01 Mn |
| Jun 30, 2024 | -21.81 Mn |
| Mar 31, 2024 | -20.98 Mn |
| Dec 31, 2023 | -21.51 Mn |
| Sep 30, 2023 | -20.18 Mn |
| Jun 30, 2023 | -27.87 Mn |
| Mar 31, 2023 | -19.58 Mn |
| Dec 31, 2022 | 56.86 Mn |
| Sep 30, 2022 | -16.49 Mn |
| Jun 30, 2022 | -16.96 Mn |
| Mar 31, 2022 | -18.51 Mn |
| Dec 31, 2021 | 27.74 Mn |
| Sep 30, 2021 | -17.20 Mn |
| Jun 30, 2021 | -45.25 Mn |
| Mar 31, 2021 | -14.85 Mn |
| Dec 31, 2020 | 750,000.00 |
| Sep 30, 2020 | -8.68 Mn |
| Jun 30, 2020 | -5.72 Mn |
| Mar 31, 2020 | -7.03 Mn |
| Dec 31, 2019 | -10.70 Mn |